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Abstract
Objective
Invasive cervical cancer (ICC) is the fourth most common cancer among women worldwide.
Cervical screening programs have reduced the incidence and mortality rates of ICC. We
studied the cost-effectiveness of different cervical screening strategies in the Islamic
Republic of Iran, a Muslim country with a low incidence rate of ICC.
Methods
We constructed an 11-state Markov model, in which the parameters included regression
and progression probabilities, test characteristics, costs, and utilities; these were extracted
from primary data and the literature. Our strategies included Pap smear screening and
human papillomavirus (HPV) DNA testing plus Pap smear triaging with different starting
ages and screening intervals. Model outcomes included lifetime costs, life years gained,
quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs). One-
way sensitivity analysis was performed to examine the stability of the results.
Results
We found that the prevented mortalities for the 11 strategies compared with no screening
varied from 26% to 64%. The most cost-effective strategy was HPV screening, starting at
age 35 years and repeated every 10 years. The ICER of this strategy was $8,875 per QALY
compared with no screening. We found that screening at 5-year intervals was also cost-
effective based on GDP per capita in Iran.
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Conclusion
We recommend organized cervical screening with HPV DNA testing for women in Iran,
beginning at age 35 and repeated every 10 or 5 years. The results of this study could be
generalized to other countries with low incidence rates of cervical cancer.
Introduction
Invasive cervical cancer (ICC) is the fourth most common cancer among women worldwide
[1]. The highest age-standardized incidence rate (ASR) has been reported in Eastern Africa
(ASR: 42.7 per 100,000) in 2013) [1]. ICC is a preventable disease, and cervical screening pro-
grams using the Pap smear procedure have an essential role in reducing the incidence and mor-
tality rate of ICC in many countries, including the United States, United Kingdom, and Nordic
countries, among others [2–4]. This decline seems to be limited to high-income countries, but
80% of ICCs occur in low- and middle-income countries [5, 6].
Human papillomavirus (HPV) infection is known as a necessary cause of ICC [7, 8]. As a
result, HPV DNA testing has recently emerged as a novel and effective screening method. HPV
vaccination has been widely recommended for prevention of HPV infection and therefore, pre-
vention of ICC [9]. HPV DNA testing methods have higher sensitivity than Pap smear testing
for detection of precancerous lesions [10]; therefore, Pap smear screening requires more fre-
quent testing with shorter intervals compared with HPV DNA testing. Another limitation of
Pap smear is its dependency on cytological techniques, which require relatively more highly
trained personnel compared with HPV DNA testing, in which advanced and automated are
used [11]. Moreover, aside from the type of screening test, the starting age, screening intervals,
and participation rate of women are important factors for an effective screening program. For
both Pap smear and HPV testing methods, specificity is likely to increase with increased age at
screening [12], and HPV triage of women aged 35 or older is more effective than in younger
women [13, 14].
Cost is another characteristic of a screening program that should be taken into account
along with its effectiveness. In fact, health policy makers tend to choose the most cost-effective
screening method for public health programs. Results of economic evaluation studies may be
important in such decision-making processes [15]. Cost-effectiveness studies provide an ana-
lytical tool to decide which intervention is suitable for implementation of screening in the tar-
get population [16]. However, most studies comparing Pap smear with HPV DNA testing for
cervical screening have been conducted in developed countries and data from low-and middle-
income countries are limited [17].
The incidence rate of ICC is about 5 per 100,000 in the Islamic Republic of Iran, and its
peak is a decade earlier than that in high-income countries [18]. Because of the low incidence
rate of ICC, there is no organized program for prevention of ICC in Iran, and patients are usu-
ally diagnosed in advanced stages with poor prognosis. Women who are 21–69 years of age are
offered Pap smear testing every 3 years if they are referred to health care centers or a gynecolo-
gist for any reason. In this approach, called opportunistic screening, the decision about screen-
ing take place in the clinical setting and depends on the initiative of each woman or her doctor
[19]. In opportunistic screening, some women may be screened frequently whereas others may
never attend the screening. This type of screening is ineffective and has been discouraged
because of its poor quality and low coverage [19, 20]. In contrast, an organized screening pro-
gram is a high standard of service that offers screening to the target population by active
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invitation and follow-up. An organized program is usually monitored regularly to ensure the
program’s coverage and quality. Based on a recent priority setting study, development and
implementation of an organized screening program and decisions about the proper age, inter-
vals, and tests for screening are considered important priorities for Iran [21].
In this study, we aimed to perform an economic evaluation and suggest the most cost-effec-
tive ICC screening strategy, including the type of test and screening schedule for low-risk pop-
ulations in Iran. The results of this study could be generalized to other countries with low
incidence rates of ICC in which governments are hesitant to introduce cervical screening
programs.
Materials and Methods
Decision Model
We constructed an 11-state Markov cohort model of women to estimate the lifetime cost, qual-
ity-adjusted life years (QALY), incidence number, and mortality of ICC using 11 different
screening strategies in comparison to no screening strategy. The time horizon was lifetime. All
costs and QALY were discounted at an annual rate of 3%. All analyses were performed using
TreeAge Pro 2011 software (TreeAge Software Inc., Williamstown, MA, USA).
Natural History of ICC
Wemodeled the natural history of ICC in 11 health states, including healthy, HPV infection,
low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion
(HSIL), cancer stage I, cancer stage II, cancer stage III, cancer stage IV, death from cancer,
death from other causes, and survived state. We simulated a cohort in which a healthy woman
can move between different states in the Markov model. Each cycle was equal to 1 year, and the
model simulated the natural history of ICC in women over 15 years of age.
During simulation in the healthy state, women could remain healthy or progress to the
HPV infection state in one cycle. Women with HPV infection could progress to the LSIL or
HSIL state, stay in the HPV infection state, or regress to the healthy state in 1 year. Every
woman in the LSIL state could remain in the LSIL state, progress to the HSIL state, or regress
to the HPV infection or healthy state. Women in the HSIL state could progress to cancer stage
I, remain in the same state, or regress to the LSIL, HPV infection, or healthy state. Women in
each of the four stages of cancer (I–IV) could only progress to the next stage of cancer, remain
at the same stage, or die of cancer. We considered no regression for ICC in the model. If a
woman survived for 5 years, she could progress to the survived state. Each woman in any state
could die from other causes.
Model Assumptions
Our model had the following assumptions:
1. All women undergo the screening program, and the screening coverage is 100%.
2. Every woman entered into the model is in the healthy state.
3. Even after clearance from HPV infection and treatment, there is a chance of reinfection
with HPV.
4. Every woman with abnormal cervical cells will return to a routine screening program imme-
diately after follow-up and treatment of her precancerous lesions.
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Screening Strategies
We conducted a cost-effectiveness study and compared 11 screening strategies with no screen-
ing in terms of costs and effectiveness. One strategy was the current screening recommendation
in Iran, i.e., cervical screening every 3 years for women ages 21–69 years. Other strategies were
selected based on comparing new screening technology (HPV DNA testing) and old technol-
ogy (Pap smear) with a combination of different starting ages and screening intervals. The
starting age ranged from 21 to 35 years and intervals were 3, 5, and 10 years. Pap smear triage
was used for all strategies.
We stopped all strategies in our model at the age of 65 years and the simulation model con-
tinued until all women in the cohort had died. We used international guidelines for the process
of each screening method (i.e., Pap smear or HPV DNA testing) and then consulted with gyne-
cologists so as to standardize the process for Iran. We have published details about the process
elsewhere [22].
We did not include visual inspection with 4% acetic acid (VIA) because it has the lowest
sensitivity and specificity and is usually recommended for low-resource settings [23–25]. In
addition, we did not compare liquid-based cytology (LBC) in this analysis because there are no
significant differences between LBC and Pap smear in terms of test characteristics and LBC has
a higher cost compared with conventional Pap smear [26].
Description of Strategies
Pap smear 21–3: Pap smear starting at age 21 for 3 consecutive years and then every 3 years.
Pap smear 30–3: Pap smear starting at age 30 with 3-year intervals.
Pap smear 30–5: Pap smear starting at age 30 with 5-year intervals.
Pap smear 30–10: Pap smear starting at age 30 with 10-year intervals.
Pap smear 35–3: Pap smear starting at age 35 with 3-year intervals.
Pap smear 35–5: Pap smear starting at age 35 with 5-year intervals.
Pap smear 35–10: Pap smear starting at age 35 with 10-year intervals.
HPV 30–5: HPV DNA testing starting at age 30 with 5-year intervals.
HPV 30–10: HPV DNA testing starting at age 30 with 10-year intervals.
HPV 35–5: HPV DNA testing starting at age 35 with 5-year intervals.
HPV 35–10: HPV DNA testing starting at age 35 with 10-year intervals.
Model Parameters
Parameters of the natural history. We found no data of the incidence rate of HPV infec-
tion in Iran. Therefore, similar to previous studies [27–32], we used calibration methods based
on the stage and age-specific rate of ICC in Iran to estimate the age-specific incidence rate
of HPV infection, using data from the national cancer registry and Globocan 2012 [1, 33].
Because the ranges of progression and regression of HPV incidence are fairly consistent inter-
nationally, we used data from the literature to obtain the regression, progression, and persistent
probability for each state [28,29,34,35].
We obtained the mortality rate of the general Iranian population from the life table pub-
lished by the World Health Organization (WHO) for Iran [36]. In addition, we used 1-, 2-, 3-,
4-, and 5-year survival of ICC and stage-specific survivals based on a recent multicenter study
in the capital city of Tehran [37] (Table 1).
Characteristics of the screening test. Because HPV DNA testing is not currently used for
cervical screening in Iran, we failed to find local HPV DNA test characteristics. We obtained
test characteristics for HPV DNA testing using polymerase chain reaction (PCR) from a
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Table 1. Model parameters (transition probabilities, screening test characteristics, quality of life, and
costs), baseline values, and references.
Parameters Base case References
Natural History
Probability of transition of Well to HPV Age-dependent calibration
Probability of transition [45,47–49]
Probability of Transition of HPV to Well 15–85 years 0.7
Probability of Transition of HPV to LSIL 15–85 years 0.072
Probability of Transition of HPV to HSIL
15 years 0.032
85 years 0.042
Probability of Transition of LSIL to Well
15 years 0.16
85 years 0.081
Probability of Transition of LSIL to HPV
15 years 0.16
85 years 0.082
Probability of Transition of LSIL to HSIL
15 years 0.017
85 years 0.069
Probability of Transition of HSIL to Well 0.069
Probability of Transition of HSIL to HPV 15–85 years 0.05
Probability of Transition of HSIL to LSIL 15–85 years 0.069
Probability of Transition of HSIL to cancer I
15 years 0.01
85 years 0.005
Probability of detection cancer [46,49,50]
Probability of detection stage I cancer 0.15
Probability of detection stage II cancer 0.23
Probability of detection stage III cancer 0.6
Probability of detection stage IV cancer 0.9
Progression Cancer I to stage II cancer 0.437
Progression Cancer II to stage III cancer 0.535
Progression Cancer III to stage IV cancer 0.683
Survival [67]
Survival stage I cancer 0.86
Survival stage II cancer 0.63
Survival stage III cancer 0.35
Survival stage IV cancer 0.11
Test Characteristics
Sensitivity of Pap smear 0.66 [38]
Speciﬁcity of Pap smear 0.86 [38]
Sensitivity of HPV DNA testing 0.81 [14,43]
Speciﬁcity of HPV DNA testing 095 [14,43]
Speciﬁcity of colposcopy 1 [27]
Quality of Life(QALY)
Quality of life of well state 1 [40,52]
Quality of life of LSIL state 0.97 [40,52]
Quality of life of HSIL state 0.93 [40]
(Continued)
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published systematic review of the literature [14] and from locally published data [38] for the
Pap smear test (Table 1).
Utility. We used QALY for evaluating the effectiveness of cervical screening, and the vali-
dated European Quality of Life (EuroQoL) EQ-5D questionnaire [39] for patients diagnosed
with ICC based on their stage. QALY for healthy, HPV, LSIL, and HSIL states were obtained
from the international literature [40] (Table 1).
Cost data. We used direct medical costs from a health provider perspective. The screening
cost included the cost of the test (HPV or Pap), physician visit, colposcopy, biopsy, and coniza-
tion [22]. In addition, we collected data from three cancer hospitals in Tehran and estimated
the treatment costs for different stages of ICC [41]. All costs were measured based on 2013 Ira-
nian tariffs and converted to 2013 USD. Because few laboratories in Iran currently use HPV
DNA testing as their diagnostic procedure, we had no available price for this study. We there-
fore consulted with manufacturers regarding the potential costs for HPV DNA testing for
screening purposes in Iran. Estimated costs were then used in this economic analysis. We used
the lowest prices provided by manufacturers as the base case and higher prices for one-way
sensitivity analysis (Table 1).
Cost-Effectiveness Analysis
We calculated incremental cost-effectiveness ratios (ICERs) to compare the cost and effective-
ness of each screening strategy, and no screening. The strategy with the highest cost and least
effectiveness was considered the dominated strategy, and the strategy with the greatest effec-
tiveness and lowest cost the dominant or most cost-effective strategy.
We used the gross domestic product (GDP) per capita, which is suggested by the WHO as
the threshold for the most cost-effective strategy [42]. We used 1- and 2-fold GDP per capita as
Table 1. (Continued)
Parameters Base case References
Quality of life of stage I patients 0.85 Observational
Quality of life of stage II patients 0.79 Observational
Quality of life of stage III patients 0.18 Observational
Quality of life of stage IV patients 0.14 Observational
Cost(US$)
Cost of HPV DNA testing 10 Observational
Cost of Pap screening 4 [22]
Cost of biopsy of cervix 15 [22]
Cost of visit 5 [22]
Cost of colposcopy 13 [22]
Cost of conization 372 [22]
Cost of stage I cancer 2,207 Observational
Cost of stage II cancer 3,449 Observational
Cost of stage III cancer 2,485 Observational
Cost of stage IV cancer 2,864 Observational
Cost of terminal care of stage I patients 1108 Observational
Cost of terminal care of stage II patients 1732 Observational
Cost of terminal care of stage III patients 1248 Observational
Cost of terminal care of stage IV patients 1438 Observational
Cost of follow-up for cancer 497 Observational
doi:10.1371/journal.pone.0156705.t001
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the threshold to compare the selected strategies. We also compared strategies using undis-
counted effectiveness and life years gained (LYG) instead of QALY.
Sensitivity Analysis
We performed a one-way sensitivity analysis to estimate the impact of uncertainty in the differ-
ent parameters, including test characteristics (sensitivity and specificity), and the costs of HPV
DNA testing and Pap smear testing methods. We considered ranges from 71.6–98.7 for sensi-
tivity of HPV DNA testing and ranges from 81.9–96.9 for specificity of HPV DNA testing. For
Pap smear, ranges for sensitivity and specificity were 63.9–84.7 and 90.2–97.3, respectively. All
data of test characteristics were obtained from the literature [14, 43]. Regarding cost, we used
50%–75% above and below the estimated cost for sensitivity analysis.
Results
Model Validation
Our model predictions for age-specific ICC incidence and mortality rates were highly consis-
tent with the available empirical data. The age-specific incidence rate of HPV infection pre-
dicted by the model was 0.06 at age 45 years and the age-specific incidence rate of ICC was
estimated to be 17.09 per 100,000 among women aged 50–54 years. This result was within a
plausible range obtained from the published literature [44]. The mortality to incidence ratio
was 0.38, which was consistent with the ratio calculated by Globocan 2012 for Iran. [1].
Base Case
In the base case analysis, the incidence rates, mortality rates, QALY, costs, and ICERs of 11
screening strategies were compared with no screening (Table 2). The incidence and mortality
of ICC decreased from 1,322 and 509 patients in the no-screening strategy to 483 and 184
patients using Pap smear starting from age 21 with 3-year intervals, respectively. Reductions in
the incidence and mortality rates of each strategy depended on the screening methods, starting
ages, and screening intervals. We found that HPV DNA testing begun at age 35 years and
repeated every 10 years with an ICER of $8,875 per QALY was the most cost-effective strategy
(Fig 1). ICERs of all strategies were more than 1-fold the GDP per capita. Except for Pap smear
Table 2. Incidence, mortality, cost, effectiveness, ICER, and undiscounted ICER of 11 strategies compared with no screening strategy.
Strategies Incidence(No of cases) Mortality(No of cases) Cost($) QALY ICER(US $/QALY) Undiscounted ICER
No screening 1321 509 13.93 24.406 0 0
HPV 35–10 940 363 42.89 24.409 8,875 2,472
Pap smear35-10 591 229 45.39 24.409 9,080 2,589
HPV 35–5 727 281 63.69 24.411 9,087 2,554
Pap smear 35–5 779 300 66.24 24.411 9,650 2,747
HPV 30–5 674 259 76.94 24.412 10,248 2,978
HPV 30 10 933 359 50.20 24.409 10,695 3,069
Pap smear 30–5 731 281 81.03 24.412 11,189 3,276
Pap smear 30–10 974 375 53.75 24.409 11,193 3,261
Pap smear 35–3 611 236 94.70 24.413 11,362 3,251
Pap smear 30–3 543 208 119.30 24.413 13,342 3,920
Pap smear 21–3 483 184 192.04 24.414 20,492 6,234
doi:10.1371/journal.pone.0156705.t002
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begun at age 21 and repeated every 3 years, all other strategies were less than 2-fold the GDP
per capita. The GDP per capita for Iran was $6,631 in 2013.
Although Pap smear was the cost-effective method when using LYG as the outcome, HPV
DNA testing became the most cost-effective when undiscounted QALY was considered the
outcome measure (Table 3).
Fig 1. Cost-effectiveness of 11 different strategies for cervical screening. Strategies standing on the
curve are dominant strategies, indicating that they cost less and had more effect. Strategies located out of the
curve are dominated strategies, i.e. their costs were much higher than their effects.
doi:10.1371/journal.pone.0156705.g001
Table 3. The most cost-effective strategies (CES) based on different calculationmethods. The cost-effectiveness of 11 strategies were estimated with
different methods. Effectiveness was measured with QALY, LYG, and undiscounted QALY.
Calculation methods of cost-effectiveness First CES Second CES Third CES Sensitive to base
case
Base Case HPV 35–10 Pap smear 35–
10
HPV 35–5 -
Life years gained (LYG) Pap smear 35–
10
Pap smear 35–5 Pap smear 30–5 Sensitive
Undiscounted QALY HPV 35–10 HPV 35–5 Pap-smear 35–
10
Sensitive
One-way sensitivity analysis of decreasing sensitivity of HPV DNA Pap smear 35–
10
Pap smear 35–5 Pap-smear 30–5 Sensitive
One-way sensitivity analysis of decreasing sensitivity of Pap smear HPV 35–10 HPV 35–5 HPV 30–5 Sensitive
One-way sensitivity analysis of decreasing speciﬁcity of HPV DNA Pap smear 35–
10
HPV 35–10 Pap 35–5 Sensitive
One-way sensitivity analysis of decreasing speciﬁcity of Pap smear HPV 35–10 Pap smear 35–
10
HPV 30–10 Sensitive
One-way sensitivity analysis of increasing sensitivity of HPV DNA HPV 35–10 HPV 35–5 HPV 30–10 Sensitive
One-way sensitivity analysis of increasing speciﬁcity of HPV DNA HPV 35–10 Pap smear 35–
10
HPV 35–5 Not sensitive
One-way sensitivity analysis of increasing speciﬁcity of Pap smear Pap smear 35–
10
Pap smear 35–5 Pap smear 30–5 Sensitive
One-way sensitivity analysis based on increasing the cost of HPV
DNA
Pap smear 35–
10
Pap smear 35–5 Pap smear 30–5 Sensitive
One-way sensitivity analysis based on increasing the cost of Pap
smear
HPV 35–10 HPV 35–5 HPV 30–10 Sensitive
doi:10.1371/journal.pone.0156705.t003
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Sensitivity Analysis
In one-way sensitivity analysis, our model was sensitive to the cost of the selected screening
methods (i.e., Pap smear vs. HPV DNA testing) and test characteristics (Table 3). An increase
or decrease in the sensitivity of screening methods affected the results and changed the ICERs.
However, the model was not sensitive to the higher specificity of HPV DNA testing.
Discussion
We performed a cost-effectiveness study and evaluated 11 cervical screening strategies using
Pap smear and HPV DNA testing with different starting ages and testing intervals in Iran.
Compared with a no-screening strategy, the most cost-effective strategy (ICER of $8,875 per
QALY) was HPV DNA testing beginning at age 35 years with 10-year screening intervals. We
showed that compared with a no-screening situation, an organized screening program may
decrease the incidence of ICC from 974 to 483 women (26% to 63%), depending on the screen-
ing strategy.
To the best of our knowledge, this is the first economic evaluation for cervical screening in a
Muslim country with low incidence of ICC. The results of this study could be generalized to
other countries with the same risk profile. However, we faced some limitations. We lacked
local data about the natural history of ICC, incidence rate of HPV in different age groups, and
characteristics of HPV testing; we therefore used data from the international literature [45–50].
These types of data do not usually vary from country to country, and most economic studies
rely on such data [45, 51, 52]. Although we used incidence rate of HPV infection based on
reports from other countries, we eliminated potential bias through calibration and adjustment
of the results with the existing prevalence rate of infection from Iran.
The starting age and intervals of cervical screening are important factors for its effectiveness
and low cost. Different countries select screening strategies vis-à-vis these two factors.
Although an earlier starting age and shorter intervals between screening lead to a higher num-
ber of tests during a woman’s lifetime, these may improve the effectiveness of a screening pro-
gram. However, frequent screening would increase the burden and cost for the participant,
health care providers, and governments. Therefore, it has always been challenging for govern-
ments to choose the best starting age and intervals for screening. HPV infection is a sexually
transmitted disease and the prevalence of this infection is higher among women younger than
30 years of age [12]. However, women older than 30 years with persistent HPV infection are a
group at high risk for ICC [53]. As we showed in this study, beginning screening at 35 years of
age was more cost-effective than beginning at younger ages. This finding is supported by previ-
ous studies from other countries [17]. In practice, several countries including Finland, Korea,
the Netherlands, and China begin screening at age 30 [54, 55] or 35 years [31, 34, 56]; screening
starts at 25 years of age in the United Kingdom, France, Italy, and Portugal [55, 57], and age 21
in the United States and Canada [55].
Screening intervals also vary between countries. Although screening is performed every 3
years in the United States, New Zealand, and Norway, the intervals for screening is 5 years in
many countries such as Denmark, Finland, and the Netherlands [55]. Many economic evalua-
tion studies conducted in low- and middle-income countries have reported that 10- and 5-year
intervals were more cost-effective than 3-year or shorter intervals [31, 34, 45, 56, 58]. Our
study showed that expanding the screening interval to 10 years is more cost-effective than 5- or
3-year screening intervals. However, based on GDP per capita, 5-year intervals was also within
the cost-effective range. In a systematic review, we found that the governments of most coun-
tries choose screening intervals conservatively, and national guidelines usually recommend
5-year intervals for cervical screening [17]. Therefore, although HPV DNA testing from age 35
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years and repeated every 10 years was the most cost-effective strategy, 5-year intervals could be
considered for cervical screening in Iran.
In line with a recent systematic review, we found that HPV DNA testing was a more cost-
effective method compared with Pap smear for cervical screening and prevention of ICC [17].
This result may encourage policy makers to plan for implementation of HPV DNA testing in
Iran and other low incidence populations. There are other advantages to shifting from conven-
tional Pap smear to HPV DNA techniques [59–61]. HPV DNA testing is more acceptable and
more convenient for both participants and providers [11, 62]. HPV DNA testing can be done
using self-sampling methods and can thus improve the coverage of screening in target popula-
tions [62]. The use of HPV DNA testing for cervical screening is still evolving. Although most
HPV testing strategies are combined with Pap smear triage, randomized trials have shown the
superiority of HPV DNA testing alone compared with Pap smear screening [63]. In 2014, the
US Food and Drug Administration (FDA) approved primary screening using HPV DNA test-
ing [64], which has a simpler procedure and lower screening cost yet is as effective as other
HPV DNA testing strategies [65]. Furthermore, using more sensitive methods such as cobas1
or Hybrid Capture 2 rather than PCR can improve the cost-effectiveness of HPV DNA testing
for cervical screening [66].
Conclusion
We performed a cost-effectiveness study and showed that organized cervical screening using
HPV DNA testing, starting from age 35 and repeated every 10 years, was the most cost-effec-
tive strategy for Iran, a middle-income country with a low incidence rate of ICC. Our findings
reflect that a more conservative approach was also cost-effective based on GDP per capita in
Iran, with screening from age 35 with 5-year intervals. We suggest conducting a demonstration
project in a limited geographical area of the country to evaluate the feasibility and cost of an
organized screening program using HPV DNA testing. The results of such a study can provide
empirical evidence for the effectiveness and cost-effectiveness of screening by HPV DNA test-
ing, to help pave the way for a national program in the near future.
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